Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS

Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep M. Marti, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Jianping Wang, Maria Krevvata, Jaclyn Stanziola, Matteo Loi, Emilie M.J. Van Brummelen, Lorena Lopez-Masi, Melissa Rowe, Robin L. Carson, Sonja Zweegman

Open source

DOI
10.1200/jco-26-00401
Published
2026-09-25
Container
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-00401,
  title = {Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS},
  author = {Saad Z. Usmani and Thierry Facon and Vania Hungria and Nizar J. Bahlis and Christopher P. Venner and Marc Braunstein and Ludek Pour and Josep M. Marti and Supratik Basu and Yael C. Cohen and Morio Matsumoto and Kenshi Suzuki and Cyrille Hulin and Sebastian Grosicki and Wojciech Legiec and Meral Beksac and Angelo Maiolino and Hiroyuki Takamatsu and Aurore Perrot and Mehmet Turgut and Weiping Liu and Jianping Wang and Maria Krevvata and Jaclyn Stanziola and Matteo Loi and Emilie M.J. Van Brummelen and Lorena Lopez-Masi and Melissa Rowe and Robin L. Carson and Sonja Zweegman},
  year = {2026},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-26-00401},
  url = {https://doi.org/10.1200/jco-26-00401}
}

RIS

TY  - JOUR
TI  - Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS
AU  - Saad Z. Usmani
AU  - Thierry Facon
AU  - Vania Hungria
AU  - Nizar J. Bahlis
AU  - Christopher P. Venner
AU  - Marc Braunstein
AU  - Ludek Pour
AU  - Josep M. Marti
AU  - Supratik Basu
AU  - Yael C. Cohen
AU  - Morio Matsumoto
AU  - Kenshi Suzuki
AU  - Cyrille Hulin
AU  - Sebastian Grosicki
AU  - Wojciech Legiec
AU  - Meral Beksac
AU  - Angelo Maiolino
AU  - Hiroyuki Takamatsu
AU  - Aurore Perrot
AU  - Mehmet Turgut
AU  - Weiping Liu
AU  - Jianping Wang
AU  - Maria Krevvata
AU  - Jaclyn Stanziola
AU  - Matteo Loi
AU  - Emilie M.J. Van Brummelen
AU  - Lorena Lopez-Masi
AU  - Melissa Rowe
AU  - Robin L. Carson
AU  - Sonja Zweegman
PY  - 2026
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-26-00401
UR  - https://doi.org/10.1200/jco-26-00401
ER  - 

APA

Usmani, S. Z., Facon, T., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M., Pour, L., Marti, J. M., Basu, S., Cohen, Y. C., Matsumoto, M., Suzuki, K., Hulin, C., Grosicki, S., Legiec, W., Beksac, M., Maiolino, A., Takamatsu, H., Perrot, A., Turgut, M., Liu, W., Wang, J., Krevvata, M., Stanziola, J., Loi, M., Brummelen, E. M. V., Lopez-Masi, L., Rowe, M., Carson, R. L., & Zweegman, S. (2026). Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00401

Source records